Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1352226-87-9] (S)-Ceralasertib
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-19323A |
| Brand: | MCE |
| CAS: | 1352226-87-9 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 412.51 |
| Molecular Formula | C20H24N6O2S |
| SMILES | O=[S@](C1(CC1)C2=NC(C3=C4C(NC=C4)=NC=C3)=NC(N5CCOC[C@H]5C)=C2)(C)=N |
For research use only. We do not sell to patients.
Summary
(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC 50 of 2.578 nM [1] . (S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. (S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition [2] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05514132 | AstraZeneca |
Advanced Solid Tumours
|
September 26, 2022 | Phase 1 |
| NCT03328273 | Acerta Pharma BV |
Chronic Lymphocytic Leukemia
|
July 15, 2020 | Phase 1 |
| NCT05582538 | IFOM, The FIRC Institute of Molecular Oncology|AstraZeneca |
Triple Negative Breast Cancer Metastatic
|
November 2022 | Phase 2 |
| NCT01955668 | AstraZeneca|CLL Consortium |
11q-deleted Relapsed+Refractory Chronic Lymphocytic Leukaemia (CLL),|Prolymphocytic Leukaemia (PLL)|B Cell Lymphomas
|
November 2013 | Phase 1 |
| NCT04704661 | National Cancer Institute (NCI) |
Advanced Breast Carcinoma|Advanced Colon Carcinoma|Advanced Colorectal Carcinoma|Advanced Endometrial Carcinoma|Advanced Gastric Carcinoma|Advanced Gastroesophageal Junction Adenocarcinoma|Advanced Malignant Solid Neoplasm|Advanced Salivary Gland Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|HER2-Positive Breast Carcinoma|Malignant Hepatobiliary Neoplasm|Metastatic Breast Carcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Malignant Solid Neoplasm|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colon Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Major Salivary Gland Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Colon Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Colon Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Major Salivary Gland Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Colon Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Major Salivary Gland Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Colon Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Major Salivary Gland Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Stage IVC Colon Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Stage IVC Major Salivary Gland Cancer AJCC v8|Unresectable Colorectal Carcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Malignant Solid Neoplasm
|
March 5, 2021 | Phase 1 |
| NCT03682289 | Rahul Aggarwal|AstraZeneca|University of California, San Francisco |
Clear Cell Renal Cell Carcinoma|Locally Advanced Pancreatic Cancer|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm|Metastatic Renal Cell Carcinoma|Metastatic Urothelial Carcinoma|Metastatic Pancreatic Cancer|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer
|
January 17, 2019 | Phase 2 |
| NCT03669601 | CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust |
Cancer
|
October 15, 2019 | Phase 1 |
| NCT03787680 | University of Michigan Rogel Cancer Center |
Prostate Cancer
|
October 31, 2019 | Phase 2 |
| NCT05450692 | AstraZeneca|Parexel |
Advanced or Metastatic Non-Small Cell Lung Cancer
|
September 15, 2022 | Phase 3 |
| NCT04564027 | AstraZeneca |
Advanced Solid Tumours
|
December 1, 2020 | Phase 2 |
| NCT02223923 | Royal Marsden NHS Foundation Trust|AstraZeneca|Cancer Research UK|RM+ICR Biomedical Research Centre |
Solid Tumour Refractory to Conventional Treatment
|
July 2014 | Phase 1 |
| NCT04417062 | Dana-Farber Cancer Institute|Osteosarcoma Institute|AstraZeneca |
Osteosarcoma|Osteosarcoma Recurrent
|
November 24, 2020 | Phase 2 |
| NCT03579316 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma
|
December 7, 2018 | Phase 2 |
| NCT03428607 | Samsung Medical Center |
SCLC
|
October 17, 2018 | Phase 2 |
| NCT04699838 | Muhammad Furqan|AstraZeneca|Big Ten Cancer Research Consortium |
Extensive Stage Small Cell Lung Cancer
|
April 20, 2021 | Phase 2 |
| NCT04298008 | Seoul National University Hospital |
Bile Duct Cancer|Chemotherapy Effect
|
June 25, 2020 | Phase 2 |
| NCT04065269 | Institute of Cancer Research, United Kingdom|Cancer Research UK|AstraZeneca |
Gynaecological Cancers
|
November 27, 2019 | Phase 2 |
| NCT03022409 | AstraZeneca |
Head and Neck Squamous Cell Carcinoma
|
September 18, 2017 | Phase 1 |
| NCT02576444 | Joseph Paul Eder|Dana-Farber Cancer Institute|Vanderbilt-Ingram Cancer Center|The Cleveland Clinic|Yale University |
Cancer
|
November 2015 | Phase 2 |
| NCT04298021 | Seoul National University Hospital |
Bile Duct Cancer|Chemotherapy Effect
|
June 25, 2020 | Phase 2 |
| NCT02937818 | AstraZeneca |
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
|
November 28, 2016 | Phase 2 |
| NCT02264678 | AstraZeneca |
Adv Solid Malig - H&N SCC, ATM Pro + Def NSCLC, Gastric, Breast and Ovarian Cancer
|
October 31, 2014 | Phase 1|Phase 2 |
| NCT05061134 | AstraZeneca |
Melanoma
|
August 11, 2022 | Phase 2 |
| NCT03780608 | Samsung Medical Center |
Gastric Adenocarcinoma|Malignant Melanoma
|
July 30, 2019 | Phase 2 |
| NCT02630199 | Samsung Medical Center |
Refractory Cancer
|
December 2015 | Phase 1 |
| NCT03334617 | AstraZeneca |
Non-Small Cell Lung Cancer
|
December 18, 2017 | Phase 2 |
| NCT03770429 | Massachusetts General Hospital|AstraZeneca |
Leukemia|Myelodysplastic Syndrome
|
August 5, 2019 | Phase 1 |
| NCT03833440 | Assistance Publique Hopitaux De Marseille |
Non-small Cell Lung Cancer
|
October 8, 2019 | Phase 2 |
| NCT03330847 | AstraZeneca |
Metastatic Triple Negative Breast Cancer
|
March 7, 2018 | Phase 2 |
| NCT02664935 | University of Birmingham|Cancer Research UK|AstraZeneca|Pfizer|Experimental Cancer Medicine Centres|Mirati Therapeutics Inc. |
Non-Small Cell Lung Cancer|Carcinoma, Squamous Cell|Adenocarcinoma
|
May 2015 | Phase 2 |
| NCT04090567 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Advanced Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Germline BRCA1 Gene Mutation|Germline BRCA2 Gene Mutation|HER2+Neu Negative|Metastatic Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8
|
July 28, 2020 | Phase 2 |
| NCT04239014 | AstraZeneca|Parexel |
Ovarian Cancer
|
August 7, 2020 | Phase 2 |
| NCT03878095 | National Cancer Institute (NCI) |
Malignant Solid Neoplasm|Refractory Cholangiocarcinoma|Refractory Malignant Solid Neoplasm
|
December 2, 2019 | Phase 2 |
| NCT03462342 | University of Pennsylvania|AstraZeneca |
High Grade Serous Carcinoma
|
March 9, 2018 | Phase 2 |
| NCT05469919 | AstraZeneca |
Advanced Solid Malignancies
|
June 9, 2022 | Phase 1 |
| NCT03740893 | Institute of Cancer Research, United Kingdom|AstraZeneca |
Breast Neoplasm
|
October 15, 2019 | Phase 2 |
| NCT03527147 | Acerta Pharma BV|AstraZeneca |
NHL|DLBCL|Non-hodgkin´s Lymphoma|Diffuse Large B Cell Lymphoma
|
June 19, 2018 | Phase 1 |
| NCT03801369 | OHSU Knight Cancer Institute|AstraZeneca|Oregon Health and Science University |
Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma
|
December 12, 2018 | Phase 2 |
| NCT03182634 | Institute of Cancer Research, United Kingdom|Royal Marsden NHS Foundation Trust |
Advanced Breast Cancer
|
December 15, 2016 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL ( 242.42 mM ; Need ultrasonic)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4242 mL | 12.1209 mL | 24.2418 mL |
| 5 mM | 0.4848 mL | 2.4242 mL | 4.8484 mL |
| 10 mM | 0.2424 mL | 1.2121 mL | 2.4242 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
*
All of the co-solvents are available by MCE.
References
- [1] By Foote, et al. Morpholinopyrimidines as ATR kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl. (2011), WO 2011154737 A1 20111215.
- [2] Foote KM, et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutatedand Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J Med Chem. 2018 Nov 21;61(22):9889-9907.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.